*14th International*

# MOLECULAR MEDICINE Tri-Conference

**Conference Dates:** February 27 - March 2, 2007
**Exhibit Dates:** February 28 - March 1, 2007
**Moscone North Convention Center • San Francisco, CA**

## Book Early!

The first 50 to register by October 27 will receive a copy of G. Steven Burill's Biotech 2006 - Life Sciences Book.
(See details on page 2)




**Plus! Save up to $350!**

# BRIDGING BIOLOGY CHEMISTRY & BUSINESS

1. Pathway Analysis
2. Global Strategies Executive Summit
3. Mastering Medicinal Chemistry
4. Preclinical Development
5. Molecular Diagnostics
6. Commercializing Stem Cells
7. Clinical Trials in India & Asia
8. Trends in Drug Safety
9. Cancer Molecular Markers

**Access to all 9 Tracks One Price!**

**Premier Sponsors:**

Applied Biosystems — an Applera Corporation Business
Biotage
DHARMACON RNA TECHNOLOGIES

**Corporate Sponsors:**

ChemBridge
iAdvantage
INGENUITY SYSTEMS
Jubilant Biosys

**Co-Sponsor:** THE WALL STREET JOURNAL.

**Lead Sponsoring Publications:**

Bio·IT World — Technologies Driving Discovery, Development, and Clinical Trials
GEN genetic engineering news
PharmaDD — TRACKING DISCOVERY & DEVELOPMENT
Science AAAS

**Cambridge Healthtech Institute**
250 First Avenue, Suite 300, Needham, MA 02494 • Phone: 781-972-5400 • Fax: 781-972-5425 • Toll-free in the U.S. 888-999-6288

*Tenth Annual*

# The Biotech Pharma Partnership

## Part I: Trends in Alliances, Collaborations, Acquisitions, and Other Sources of Capital: Executive Lectures and Moderated Panel • 8-11:30am

**Distinguished Faculty and Advisors:**

*Wendy Benson, Ph.D., Senior Director, Business Development,* ***Roche Molecular Diagnostics***

*Arthur H. Bertelsen, Ph.D., Executive Director, Discovery Collaborations & Technology Licensing,* ***Schering-Plough Research Institute***

*T. (Teo) Forcht Dagi, MD, MPH, MBA, FACS, FCCM,* ***HLM Venture Partners & Harvard-MIT*** *Division of Health Sciences and Technology (HST) Faculty*

*Jack DeForrest, Ph.D., Vice President of Technology Licensing, Product Acquisition and Licensing,* ***GE Healthcare***

*Kendra B. Eager, Ph.D., Assistant. Vice President, Alliance Management,* ***Wyeth Global Business Development***

*Cynthia Grant, Ph.D., Associate Global Alliance Director, Global Sciences and Information,* ***AstraZeneca Pharmaceuticals***

*Stefanie Hansen, J.D., Director, Strategic Alliances,* ***Pfizer Global Research and Development***

*Robert C. Hockney, Ph.D., Director, Global Discovery Alliances, GSI,* ***AstraZeneca R&D***

*Rosemarie Hunziker, Ph.D., Director, Technology Development and Industrial Relations, Center for Biotechnology and Innovation, National Institute of Dental and Craniofacial Research,* ***National Institutes of Health***

*Jeremy Levin, D. Phil, MB. Bchir, Global Head, Business Development and Strategic Alliances,* ***Novartis***

*Kelly P. Longo, Ph.D., Director, Strategic Alliances,* ***Pfizer Inc.***

*John Iwanicki, Patent Attorney, Senior Partner,* ***Banner & Witcoff, Ltd.***

*Joan Lasota, Ph.D., Senior Director Alliance Management,* ***Merck & Co.***

*Michael O. Ransom, Ph.D., Alliance Manager, Eli Lilly & Co., Lilly Corporate Center,* ***Lilly Research Labs***

*Sanra Rivett, Ph.D., Associate Global Alliance Director, Global Sciences and Information,* ***AstraZeneca Pharmaceuticals***

*Steven Tregay, Ph.D., Head of Strategic Alliances Technology,* ***Novartis***

**Keynote Topics & Panel Discussion will include presentations on:**

- Alliance Management
- Licensing and Protecting Assets
- Merges and Acquisitions
- The Strategic Role of Partnerships and other Collaborations that Fund the Pipeline

## Part II: Early Stage Company Presentations, Executive Coaching & Didactic Panel Critiques • 1-4pm

Three concurrent sessions in: • Diagnostics • Biomarkers • Cancer Therapeutics

Each session will be moderated and critiqued by the part I program experts in Alliances, Licensing, Funding, and Intellectual Property. Selected early stage companies have been reviewed and selected by our scientific and business advisors. (Limited openings still available). Please contact samster@healthtech.com

**Roundtable Networking Reception Discussion Groups**

"Meet and Greet" executive speakers, panelists and early stage company representatives at moderated roundtable networking discussion groups.

**One-to-One Meetings Available all Week Using CHI's Intro-Net**

## Short Courses (SC)

### MORNING

**(SC1)** The Biotech Pharma Partnership - Part I

**(SC2)** Global Strategies Morning Course

**(SC3)** Novel Therapies for CNS Disorders - Crossing the Blood-Brain Barrier
*see pg. 5 for details*

**(SC4)** Microreactors: Integrating Flow Chemistry into Drug Discovery
*see pg. 5 for details*

**(SC5)** Circulating Tumor Cells (CTCs) as Biomarkers and their use in Oncology Clinical Trial Design
*see pg. 7 for details*

**(SC6)** Preclinical Morning Course

### AFTERNOON

The Biotech Pharma Partnership - Part II

**(SC7)** Diagnostics

**(SC8)** Biomarkers

**(SC9)** Cancer Therapeutics

**(SC10)** An Interactive Workshop Including a Business War Game: Does Your Strategy Hurt When I Do This?
*see pg. 4 for details*

**(SC11)** ADMET Case Studies from a Medicinal Chemistry Perspective
*see pg. 5 for details*

**(SC12)** Multi-Plexing and Multi-Probing using Late-PCR and Sloppy Beacons: Applications in Quantitative End-Point Detection
*see pg. 7 for details*

**(SC13)** Microdosing

**(SC14)** Stem Cell Afternoon Course

### DINNER

**(DC15)** New Ways to Partner in the Personalized Medicine Space
*see pg. 7 for details*

## CONFERENCE-AT-A-GLANCE

| Tuesday, February 27 | Wednesday, February 28 | Thursday, March 1 | Friday, March 2 |
|---|---|---|---|
| Pre-Conference Events | 1 Pathway Analysis | 1 Pathway Analysis | 1 Pathway Analysis |
| | 2 Global Strategies to Reinvent the R&D Business Model- Executive Summit | 2 Global Strategies to Reinvent the R&D Business Model- Executive Summit | 2 Global Strategies to Reinvent the R&D Business Model- Executive Summit |
| | 3 Mastering Medicinal Chemistry | 3 Mastering Medicinal Chemistry | 3 Mastering Medicinal Chemistry |
| | 4 Predictive Preclinical Development | 4 Predictive Preclinical Development | 4 Predictive Preclinical Development |
| | 5 Molecular Diagnostics | 5 Molecular Diagnostics | 5 Molecular Diagnostics |
| | 6 Commercial Implications of Stem Cell Research | 6 Commercial Implications of Stem Cell Research | 6 Commercial Implications of Stem Cell Research |
| | 7 Clinical Trials in India & Asia | 7 Clinical Trials in India & Asia | 7 Clinical Trials in India & Asia |
| | 8 Trends in Drug Safety | 8 Trends in Drug Safety | 8 Trends in Drug Safety |
| | 9 Cancer Molecular Markers | 9 Cancer Molecular Markers | 9 Cancer Molecular Markers |

**Book Early!***

The first 50 people to register by October 27 will receive a complimentary copy of G. Steven Burrill's Biotech 2006—Life Sciences: A Changing Prescription book and save up to $350 off your event registration!

BURRILL & COMPANY

*Promotional Terms:

- 3-day registration + 1 Short Course must be paid in full by October 27, 2006
- A $395 cancellation fee will be incurred on any cancellation that qualifies for the Book Early Promotion. ($100 processing fee and $395 for the cost of the Biotech 2006 - Life Science Book.)
- Biotech 2006 - Life Science Book will be shipped out the week after the October 27th deadline

## PLENARY KEYNOTES

**Clinical Qualification and Acceptance of Biomarkers and Surrogate Endpoints**
*Steven A. Williams, M.D., Ph.D., Executive Director & Worldwide Head, Clinical Technology & R&D, Pfizer Inc.*

**Partnering and Alliance Trends**
*Iain Dukes, M.A., Dphil., Vice President, Scientific & Technology Licensing, World Wide Business Development, GlaxoSmithKline*

## PATHWAY DATABASES FOR CANCER RESEARCH

*Dr. Nathan Siemers, Director of Bioinformatics, Bristol-Myers Squibb Company*

**The New Kid on the Block: microRNA Profiling in Cancer from a Bioinformatics Perspective**
*Yuriy Gusev, Ph.D., Assistant Professor, Department of Surgery, Adjunct Assistant Professor, Institute for Breast Health, Co-Director, Bioinformatics Core facilities, OU Cancer Center, University of Oklahoma*

## OPEN SOURCE PATHWAY INFORMATION: OPPORTUNITIES AND CHALLENGES

**GenMAPP**
*Bruce R. Conklin, M.D., Associate Investigator Gladstone Institute of Cardiovascular Disease, Associate Professor of Medicine, University of California, San Francisco*

**Open Source Pathways Databases: The Reactome Example**
*Peter G. d'Eustachio, Ph.D., Editor-in-Chief, Reactome, and Associate Professor of Biochemistry and Medicine, Departments of Biochemistry and Medicine, New York University School of Medicine*

**Pathway Commons - Convenient Access to Pathway Information**
*Gary Bader, Ph.D., Assistant Professor, Banting and Best Department of Medical Research, University of Toronto*

**Integrating Genetic, Functional Genomic, and Bioinformatic Data in a Systems Biology Approach to Complex Diseases (Cytoscape)**
*Allan Kuchinsky, Principal Project Scientist, Molecular Technologies Lab, Agilent Laboratories*

## RNAi SCREENS FOR TARGET DISCOVERY

**RNAi Screens for Target Discovery in Metabolic Disease**
*Michael P. Czech, Ph.D., Professor and Chair, Program in Molecular Medicine, University of Massachusetts Medical School*

**RNAi-Based High-Content Screening for Target Identification**
*John F. Reidhaar-Olson, Ph.D., Research Leader, Department of Research Informatics, Genetics & Genomics, F. Hoffman-La Roche, Inc.*

**Screening for Drugable Inflammation Targets**
*Zaklina Strezoska, Ph.D., Senior Scientist, ALTANA Pharma AG*

**Robust, Image-Based, RNAi Screens for Oncology Drug Target Identification**
*Steven A. Haney, Ph.D., Group Leader, Oncology Genomics, Department of Biological Technologies, Wyeth Research*

**High-Throughput RNAi Screening by Time-Lapse Imaging of Live Human Cells**
*Jan Ellenberg, Ph.D., Gene Expression & Cell Biology & Biophysics, MitoCheck Project Group, European Molecular Biology Laboratory (invited)*

## EXPANDING WORLD OF microRNAs: NEW AVENUES FOR DIAGNOSTICS AND THERAPY

**miRNAs: Biomarkers for Cancer?**
*Aimee Jackson, Ph.D., Research Fellow, Rosetta Inpharmatics, a wholly-owned subsidiary of Merck & Co, Inc.*

**microRNA as Cancer Biomarkers**
*David Brown, Ph.D., Head of R&D, Asuragen, Inc.*

**Genomics of Chronic Lymphocytic Leukemia microRNAs as New Players with Clinical Significance**
*George Calin, M.D., Ph.D., Research Assistant Professor, Molecular Virology, Immunology & Medical Genetics Department, Comprehensive Cancer Center, Ohio State University*

**microRNAs in Proliferation and Differentiation**
*Anindya Dutta, M.D., Ph.D., Byrd Professor of Biochemistry and Molecular Genetics, University of Virginia*

## USE OF ANIMAL MODELS TO VALIDATE GENE EXPRESSION SIGNATURES

**Cholinergic Angiogenesis -- A Novel Endogenous Angiogenic Pathway and its Therapeutic Application to Diseases**
*Jenny Wu, Ph.D., Senior Research Scientist, Cardiovascular Medicine, Stanford University*

**Understanding Anti-Proliferation Mechanism in Animal Models by Genomic Approaches**
*Chris Huang, Ph.D., Principal Research Scientist, Discovery Research, Centocor Research & Development, Inc.*

**Organ-Specific Metastasis and Molecular Signatures**
*Andrew J. Minn, M.D., Ph.D., Assistant Professor, Department of Radiation Oncology, University of Chicago (tentative)*

**Reversible Type-2 Diabetes Mouse Model Through Doxycycline Regulated ShRNA Expression**
*Jost Seibler, Ph.D., RNAi Group Leader, Artemis Pharmaceuticals*

**Understanding Transcriptional Networks with Cap Analysis Gene Expression (CAGE)**
*Piero Carninci, Ph.D., Genome Science Laboratory, RIKEN*

## CANCER MOLECULAR MARKERS

*(Shared session with Molecular Diagnostics)*

**Developing Pharmacodiagnostics for Cancer**
*Jan Trost Jorgensen, M.S. Pharm, Ph.D., Principal Scientist, Clinical Research, Dako*

**Biomarkers and Development of Targeted Therapies**
*Mikael von Euler, M.D., Ph.D., Vice President, Oncology Clinical Development, GlaxoSmithKline*

**Regulatory Aspects of Cancer Biomarkers - an EMEA Perspective**
*Michel E. Marty, Head, Centre for Therapeutic Innovations in Oncology and Haematology, Saint Louis University Hospital, and EMEA Advisor*

**Driving Down Development Costs by Using Biomarkers**
*Karol Sikora, M.A., MBBCh, Ph.D., FRCR, FRCP, FFPM, Professor of Cancer Medicine, Medical Solutions PLC*

**Detection of Cancer through Circulating DNA**
*Devin Dressman, Ph.D., Ludwig Center for Cancer Genetics & Therapeutics, The Johns Hopkins Kimmel Cancer Center (invited)*

# GLOBAL STRATEGIES TO REINVENT THE R&D BUSINESS MODEL

**February 28-March 2, 2007**



**INTEGRATE Licensing, Alliance management, International Collaborations and Lean Thinking Into Your Organization**

## PRE-CONFERENCE SHORT COURSES (SC)

**(SC2) Morning Course**

**(SC10) An Interactive Workshop Including a Business War Game: Does Your Strategy Hurt When I Do This?**

*Mark Chussil, Founder and CEO, Advanced Competitive Strategies, Inc.*

## PLENARY KEYNOTE

**Partnering and Alliance Trends**

*Iain Dukes, M.A., Dphil., Vice President, Scientific & Technology Licensing, World Wide Business Development, GlaxoSmithKline*

## NEW APPROACHES, NEW PARADIGMS AND NEW BUSINESS MODELS FOR STRUCTURING R&D FOR LONG-TERM VIABILITY

Chairperson's Remarks

*Andrew L. Hopkins, Ph.D., Associate Research Fellow, Knowledge Discovery, Pfizer Global R&D*

**Complementing Internal R&D with External Innovation and Integrated Partnership Strategies: Driving Value through Proactive Alliance Management**

*Lorenz Ng, M.D., Ph.D., Vice President, Research & Alliance & Business Development, Asia Pacific, Eli Lilly & Co. (Asia)*

**Pharmacogenetics Discovery and Development for New Medicines**

*Dan Burns, Ph.D., Senior Vice President, Therapeutic Matrix, Compliance and Pharmacovigilance, GlaxoSmithKline*

**Is Drug Development, as We Know it Today, Going the Way of the Dinosaurs?**

*Eliot R. Forster, Ph.D., Vice President, Development, Pfizer Inc.*

## PARTNERING AND COLLABORATION STRATEGIES FOR PHARMA AND BIOTECH

Chairperson's Remarks

*James F. Resch, Ph.D., Director Strategic Intelligence, Global Discovery Strategy Portfolio & Alliances, AstraZeneca Pharmaceuticals, Inc.*

**Collaborative Mechanisms - Innovative Models and Approaches for the Life Sciences**

*Christina Sampogna, Directorate for Science, Technology and Industry, Organization for Economic Cooperation and Development (OECD)*

### Case Study

**Building Strong Partnerships with Academia and Biopharma Companies in China**

*Mao Mao, M.D., Ph.D., Associate Director/China Project Liaison, Oncology Clinical Research, Merck Research Laboratories (invited)*

**Outside Funding of Development Programs without Transfer of IP or Loss of Control**

**Creative Thinking about and Models for Financing Large, High-Risk, Long-Term Investments that Could Lead To Biomedical Breakthroughs: FasterCures' Acceleration Agenda**

*Greg Simon, President, FasterCures – Center for Accelerating Medical Solutions*

## INTERNATIONAL COLLABORATIONS & OUTSOURCING: INTEGRATING EXTERNAL AND INTERNAL RESOURCES

*Chairperson's Remarks*

*Steven M. Hutchins, Senior Director, Global Basic and Preclinical Sourcing, Merck & Co.*

**Outsourcing of R&D and Manufacturing: Regulatory Oversights on International Collaborations**

*Subhash Dhawan, Ph.D., Senior Investigator and Chief, Immunopathogenesis Section, US Food and Drug Administration (CBER)*

**Pharma Innovation and Clinical Development in China**

*James Cai, Ph.D., Vice President, Research and Development, AstraZeneca China*

## IMPROVING DISCOVERY AND DEVELOPMENT PRODUCTIVITY BY GOING GLOBAL: LEVERAGING EMERGING GLOBAL MARKETS

**Leveraging Capabilities in China, India and other Emerging Countries: Successfully Assessing Feasibility, Modeling Options, and Evaluating Partners for Emerging Capabilities**

*Eugene Williams, CEO, Cambridge Healthtech Associates*

*Eric Meyers, General Manager, Global Developer, Cambridge Healthtech Associates*

### Panel Discussion

**Strategies for Successful Outsourcing of Preclinical Development in Asia**

*Chairperson: Jay Stoudemire, Ph.D., Vice President, Preclinical Development, Ascenta Therapeutics, Inc.*

## OVERCOMING IP, QUALITY, INFRASTRUCTURE, COMMUNICATION AND CONTROL ISSUES IN EMERGING REGIONS

Chairperson's Remarks

*Balu Balasubramanian, Ph.D., Director, Discovery Chemistry, Bristol-Myers Squibb Co.*

**Strategies to Minimize IP Risk and Maximize Protection in the Rapidly Developing Legal Landscape**

**Capitalizing on Asia's Unique Characteristics to Improve R&D's Productivity**

*Eric Morfin, Director, Project Management Office, Novartis Vaccines and Diagnostics*

**Building a High-Performing, Multinational R&D Organization in China**

### Case Study

**Opportunities and Pitfalls of Establishing an R&D Service Organization in India**

*Antal K. Hajos, Ph.D., Managing Director, ALTANA Pharma Priv. Ltd.*

### Panel Discussion

**The Impacts of and Strategies for Outsourcing of Medicinal Chemistry**

*M. Bhupathy, Ph.D., Director, Chemical Process R&D, Amgen, Inc.*

*Frederik Deroose, Ph.D., Head, External Chemistry & Outsourcing Services, J&J PRD*

## STRATEGIES FOR LOWERING ATTRITION, IMPACTING SUCCESS AT PROOF-OF-CONCEPT & IMPROVING PROCESSES

Chairpersons' Remarks

*Mark I. Cockett, Ph.D., Vice President, Applied Genomics, Bristol-Myers Squibb Co.*

**R&D Productivity Levers - Are all Productivity Improvements Equal?**

*Aaron Schacht, Executive Director, R&D Strategy, Portfolio & Project Management, Eli Lilly*

**Is Drug Discovery Ready for Lean Thinking?**

*Edward W. Petrillo, Ph.D., retired Distinguished Research Fellow, Bristol-Myers Squibb Co.; President, Discovery Performance Strategies LLC*

### Case Studies

**Peptide Therapies and Research Program Planning: Marrying Research Innovation with Project, Portfolio and Resource Management to Deliver Significant New Peptide-Based Therapeutics**

*James Paterniti, Ph.D., Senior Director, Research Program Planning, Amylin Pharmaceuticals,*

**Learning from Non-Pharma Industries: Understanding Others' Mastery of Processes**

**How Wyeth is Transforming R&D: The Learn and Confirm Model of Clinical Development**

*Matthew Bell, Ph.D., MA, Senior Director, Learn and Confirm Implementation Office, Wyeth*

**Topic to Be Announced**

*Christine Cioffe, Vice President, R&D Portfolio Management, Merck & Co.*

## SUCCEEDING IN A FUTURE OF HIGH ATTRITION BY EFFECTIVELY MANAGING R&D PROJECTS AND PROCESSES

Chairperson's Remarks

*Edward W. Petrillo, Ph.D., retired Distinguished Research Fellow, Bristol-Myers Squibb Co.; President, Discovery Performance Strategies LLC*

### Case Study

**Life Science Industries - Managing a Turbulent Future**

*Professor Joyce Tait, CBE, FRSE, Ph.D., Director, ESRC Innogen Centre (Centre for Social and Economic Research on Innovation in Genomics), University of Edinburgh*

**R&D Performance Measurements: More than Choosing a Set of Metrics**

*Shama Kajiji, Ph.D., MBA, Director, WorldWide Project Management, Pfizer Inc.*

### Panel Discussion

**Effectively Managing R&D Projects and Processes: Successes and Failures**

TRACK : 3

*Fourth Annual*

# MASTERING MEDICINAL CHEMISTRY

*Delivering Pre-Development Compounds in Multiple Therapeutic Areas*

**February 28-March 2, 2007**

Corporate Sponsor: Chem Bridge

**LEARN Strategies to Tackle Difficult Targets in Mutiple Therapeutic Areas**

## PRE-CONFERENCE SHORT COURSES (SC)

*February 27, 2007*

**(SC3) Novel Therapies for CNS Disorders - Crossing the Blood-Brain Barrier**

- Novel Targets Identification and Validation
- Novel Delivery Strategies
- Dealing with the Liability of CNS Drug Side-effects
- Crossing the Blood-Brain Barrier - BBB Penetration
- Pharmacokinetics and Drug Metabolism

**(SC4) Microreactors: Integrating Flow Chemistry into Drug Discovery**

- The Challenges of Switching from Batch to Flow Chemistry
- Scaling Up and Improving Safety
- Reproducibility
- Performing Reactions with Different Solvents
- Handling Precipitates and Solids – Is there a "Solution" in Sight?
- Are Microreactors Ready for General Use in Drug Discovery Laboratories?

**(SC11) ADMET Case Studies from a Medicinal Chemistry Perspective**

- Understanding How to Evaluate ADME Data
- Diagnostic PK Assays
- QSAR for Medicinal Chemists
- Case Studies from Real Projects

## PLENARY KEYNOTE

**Partnering and Alliance Trends**

*Iain Dukes, M.A., Dphil., Vice President, Scientific & Technology Licensing, World Wide Business Development, GlaxoSmithKline*

## EXECUTIVE OVERVIEW – FUTURE DIRECTIONS FOR MEDICINAL CHEMISTRY

### Featured Speaker

**Lead Generation for Difficult Targets**

*Hanno Wild, Head of Discovery Europe, Bayer HealthCare AG*

Over the last ten years Bayer HealthCare has built up its compound library to almost 2 million single compounds. In parallel, ultra high-throughput screening in the 1536 format was established as the standard technique for lead finding. The success of this approach could be demonstrated by the discovery of novel lead structures for targets which were difficult to approach so far: Non-basic inhibitors of Factor Xa, competitive inhibitors of human neutrophil elastase, non-nucleosidic adenosine agonists.

## THE IMPACT OF OUTSOURCING AND OFF-SHORING ON MEDICINAL CHEMISTRY

- Maintaining corporate growth while increasing project capacity
- The impact of library and hit-to-lead outsourcing on medicinal chemistry
- Can current outsourcing companies provide adequate medicinal chemistry?
- Retraining medicinal chemists in more creative and higher skilled aspects of chemistry

*Frederik Deroose, Ph.D., Head of External Chemistry & Outsourcing Services, Johnson & Johnson Pharmaceutical Research & Development*

*M. Bhupathy, Ph.D., Director, Chemical Process R&D, Amgen, Inc.*

## DOMAIN DRIVEN MEDICINAL CHEMISTRY – DIFFERENT APPROACHES FOR CNS, CANCER, METABOLIC AND CHRONIC DISEASES

### Metabolic Disorders

**Selective Dipeptidyl Peptidase IV Inhibitors for the Treatment of Type 2 Diabetes: The Discovery of JanuviaTM (Sitagliptin)**

*Scott D. Edmondson, Ph.D., Senior Research Fellow, Merck Research Laboratories*

**Metabolic Disease Target Validations using Small Molecule Agents: Compare and Contrast with Genetic Depletion Models**

*Gang Liu, Ph. D., Senior Group Leader, Associate Research Fellow, GPRD-Metabolic Disease Research, Abbott Laboratories*

**PTP1B Inhibitors: New Leads for a Challenging Drug Target via Structure-based Drug Design Methods**

*Andrew Combs, Ph.D., Senior Director, Chemistry, Incyte Corporation*

**Rational Design of Potent, Selective, Efficacious and Safe DPP4 Inhibitors as a Treatment of Type 2 Diabetes**

*Zhong-hua Pei, Ph.D., Research Investigator, Metabolic Disease Research Global Pharmaceutical Research & Development, Abbott Laboratories*

**Is Malonyl-coa Decarboxylase a Viable Therapeutic Target?**

*Jie-Fei Cheng, Ph.D., Director, Chemistry, Tanabe Research Laboratories USA*

### Inflammation

**The Identification of Selective Lck Inhibitors for the Treatment of Solid Organ Transplant Rejection**

*Gavin Hirst, Ph.D., Associate Director, Medicinal Chemistry, Abbott Bioresearch Center*

### Oncology

**Progesterone Receptor Antagonists - A Successfully Completed Lead Optimization Program**

*Wolfgang Schwede, Ph.D., Senior Scientist, Medicinal Chemistry, Schering AG*

**The Discovery of SKI-606: A Dual Inhibitor of Src and Abl Kinases in Clinical Development for the Treatment of Cancer**

*Diane H. Boschelli, Ph.D., Principal Research Scientist, Chemical and Screening Sciences, Wyeth Research*

**From the Insoluble Dye Indirubin Towards Highly Active, Soluble CDK2-Inhibitors**

*Rolf Jautelat, Ph.D.,Principal Scientist, Medicinal Chemistry, Schering AG*

### CNS

**New Pharmaceuticals from Neurotransmitters: Drugs for the Brain from the Brain**

*Robin Polt, Ph.D., Professor, Chemistry/Pharmacology, The University of Arizona*

CASE STUDIES

*"This was one of the best conferences that I have been to in recent years. It combined intellectual stimulation with an exposure to the latest advances in medicinal chemistry. In addition it offered a unique opportunity to meet and talk with leaders in the field, as well as with colleagues involved in many diverse aspects of drug discovery and development."*

*Anu Mahadevan, Ph. D., Vice President, Organix, Inc. (2006 Alumna)*

TRACK : 4

Third Annual

# PREDICTIVE PRECLINICAL DEVELOPMENT

*Safety Biomarkers, Microdosing, and Selecting First Dose in Humans*

**February 28-March 2, 2007**

Sponsored By: iAdvantage

**OPTIMIZE candidate progression from DISCOVERY to EARLY CLINICAL evaluation**

**Scientific Advisory Board**

*Joy Cavagnaro, Ph.D., DABT, RAC, President, Access BIO*
*Rakesh Dixit, Ph.D., DABT, Senior Director & Global Head, Toxicology Department, MedImmune Inc.*
*David S. Lester, Ph.D., New York Site Head, WorldWide Clinical Technology, Pfizer Inc.*
*Jay Stoudemire, Ph.D., Vice President, Preclinical Development, Ascenta Therapeutics, Inc.*

## PLENARY KEYNOTES

**Clinical Qualification and Acceptance of Biomarkers and Surrogate Endpoints**

*Steven A. Williams, M.D., Ph.D., Executive Director & Worldwide Head, Clinical Technology & R&D, Pfizer Inc.*



**Partnering and Alliance Trends**

*Iain Dukes, M.A., Dphil., Vice President, Scientific & Technology Licensing, World Wide Business Development, GlaxoSmithKline*

## CANCER BIOMARKER DEVELOPMENT

### Keynote



**FDA Perspective on Cancer Biomarker Development: What are the Challenges in Bringing These to Market?**

*Larry G. Kessler, Sc.D., Director, Office of Science & Engineering Labs, FDA*

## SELECTING FIRST DOSE IN HUMANS

**New Emerging Safety Biomarkers: Utility in Preclinical and Clinical Safety Assessment**

*Rakesh Dixit, Ph.D., DABT, Senior Director and Head, Toxicology Department, Translational Sciences, MedImmune Inc.*

**Estimating First in Human Doses for Biologics: Factoring in Safety, Pharmacology and Proposed Therapeutic Dose**

*Jennifer E. Visich, Ph.D., Director, Pharmacokinetics and Pharmacodynamics, ZymoGenetics Inc.*

**The Use of Preclinical Animal Studies to Assist in Dosage Selection for Phase 1 Human Clinical Trials**

*Stanley Roberts, Ph.D., Vice President, Preclinical Development, CovX Research, LLC*

**Selecting Relevant Non-Clinical Biomarkers to Establish Human First Dose Levels**

*Christopher Horvath, D.V.M., M.S., Senior Director, Toxicology, Archemix Corp.*

**Implementing Microdosing or Phase 0 Trials**

*Richa Chandra, M.D., M.B.B.S., M.B.A., Senior Director, Clinical R&D, Translational Medicine Lead, Infectious Diseases, Pfizer Research & Development*

## OUTSOURCING PRECLINICAL DEVELOPMENT IN ASIA

**Outsourcing Preclinical ADMET to China: Opportunities and Challenges**

*Chun-Lin Chen Ph.D., President and Chief Executive Officer, Medicilon*

**China in a Global Drug Development Landscape**

*Jonathan Wang, Ph.D., General Manager, Burrill Greater China Group (BGCG), Burrill & Company*

**Outsourcing Pharmaceutical Sciences**

*Ming Guo, Ph.D, Vice President, Pharmaceutical Sciences & Manufacturing, Ascenta Therapeutics, Inc.*

### Panel Discussion

**Strategies for Successful Outsourcing of Preclinical Development in Asia**

*Chairperson: Jay Stoudemire, Ph.D., Vice President, Preclinical Development, Ascenta Therapeutics, Inc.*

## HOW MANY NEW BIOMARKERS DO WE NEED?

*Cost-Benefit Analysis of New Biomarkers*

**Barriers on the Road to New Protein Biomarkers: Confronting the Biomarker Validation Bottleneck**

*Leigh Anderson, Ph.D., Founder & Chief Executive Officer, Plasma Proteome Institute*

**Biomarkers, Biological Diversity, and Decision Making: What to Measure, What it Means, and Why it has Value**

*Thomas Paterson, Co-founder, Senior Vice President, Entelos Inc.*

**StaRT-PCR Measurement of Anti-Inflammatory Gene Transcript Abundance in Whole Blood Provides Accurate Biomarkers for RA Individuals**

*James C. Willey, M.D., Founder & Chief Science & Medical Consultant, Gene Express Inc. and Professor of Medicine and Pathology, George Isaac Professor for Cancer Research, Division of Pulmonary and Critical Care Medicine, Department of Medicine, University of Toledo*

**Too Few Qualified Biomarkers for High Value Needs**

*Howard Schulman, Ph.D., Vice President, PPD Biomarker Discovery Sciences, LLC, and Consulting Professor of Neurobiology and of Molecular Pharmacology, Stanford University*

### Panel Discussion

**Developing a Business Model for Risk Management of Innovative Technologies**

- How much do things cost? Time and money.
- What is the added value?

## CORRELATING IMAGING WITH CLINICAL EXPERIENCE

### Keynotes

*Richard Hargreaves, Ph.D., Vice President, Imaging, Merck & Co., Inc. (invited)*

*A. Gregory Sorensen, M.D., Director, Center for Biomarkers in Imaging, Associate Director, Martinos Center for Biomedical Imaging, and Associate Professor of Radiology, Harvard Medical School and Massachusetts General Hospital*

**Image-Based Biomarker Quantifications**

*Edward Ashton, Ph.D., Chief Scientific Officer, VirtualScopics, Inc.*

**Affibody Molecules, a Novel Class of Affinity Ligands for Molecular Imaging of HER2-Positive Breast Cancer Preclinical and Clinical Applications**

*Joachim Feldwisch, Ph.D., Project Manager, Research, Affibody AB*

**Imaging Biomarkers for Cognitive Enhancing and Psychotropic Therapies**

*Cameron Carter, M.D., Imaging Research Center, U.C. Davis*

*"Again, the organizers of the Molecular Medicine Tri-Conference have compiled a group of outstanding speakers/scientists in the area of preclinical/clinical drug safety to address a variety of contemporary topics/issues of high interest in the fields of pre-clinical toxicology and drug development."*

*George M., Vice President, Drug Safety & Disposition, Cephalon, Inc. (2006 Alumnis)*

TRACK : 5

Premier Sponsor: Applied Biosystems

*Fourth Annual*

# MOLECULAR DIAGNOSTICS:

*Driving Quality of Care in Medicine*

**February 28-March 2, 2007**

**DISCOVER, CHOOSE, VALIDATE, and INTRODUCE biomarker products**

## PRE-CONFERENCE SHORT COURSES

*Tuesday, February 27, 2007*

**(SC5) Circulating Tumor Cells (CTCs) as Biomarkers and their use in Oncology Clinical Trial Design**

*Chairperson: Leon Terstappen, M.D., Ph.D., Vice President of R&D, Immunicon*

**(SC12) Multi-Plexing and Multi-Probing using Late-PCR and Sloppy Beacons: Applications in Quantitative End-Point Detection**

*Lawrence Wangh, Ph.D., Associate Professor, Department of Biology, Brandeis University and Fred Kramer, Ph.D., Professor, Department of Microbiology, Public Health Research Institute*

**(DC15) New Ways to Partner in the Personalized Medicine Space**

*Moderator: Peter S. Miller, Chief Operating Officer, Genomic Healthcare Strategies*

*Panelists: Michael S. Paul, Ph.D., President & Chief Executive Officer, LineaGen Partners, Inc. Annie Brooking, Chief Executive Officer, Astron Clinica*

## PLENARY KEYNOTES

**Clinical Qualification and Acceptance of Biomarkers and Surrogate Endpoints**

*Steven A. Williams, M.D., Ph.D., Executive Director & Worldwide Head, Clinical Technology & R&D, Pfizer Inc.*

**Partnering and Alliance Trends**

*Iain Dukes, M.A., Dphil., Vice President, Scientific & Technology Licensing, World Wide Business Development, GlaxoSmithKline*

## Keynote

**FDA Perspective on Cancer Biomarker Development: What are the Challenges in Bringing These to Market?**

*Larry G. Kessler, Sc.D., Director, Office of Science & Engineering Labs, FDA*

**Interpretation of Data**

*Arthur L. Holden, M.B.A., Senior Vice President, Corporate Development, Illumina Inc.; Chairman, Pharmaceutical Biomedical Research Consortium, Ltd.*

**Special Nature of Genetic Testing**

*Paul Billings, M.D., Ph.D., Senior Vice President, Corporate Development and Strategy, LabCorp*

## CHANGING STRATEGIES AROUND BIOMARKER PARTNERSHIPS

**State of the Industry**

*Harry Glorikian, Managing Partner, Strategic Advisory, TSG Partners*

**Key Intervention Points for Global Health Diagnostics, the Impact of the Introduction of Diagnostics**

*Carol Dahl, Ph.D., Director for Global Health Technologies, Bill & Melinda Gates Foundation*

## Panel Discussion

**From Concept to Implementation - Addressing Global Health Needs**

## CASE HISTORIES IN SERUM-BASED MARKERS: THE STATE-OF-THE-ART FOR MOLECULAR DIAGNOSTICS

**Diagnosing Prion Diseases: Needs, Challenges, and Hopes**

*Claudio Soto, Ph.D., Distinguished Professor and Director Mitchell Center for Neurodegenerative Diseases, University of Texas Medical Branch, and Chief Scientific Officer and Founder, Amprion Inc.*

**Detection of EGFR in Blood May Predict Iressa and Tarceva Response in Lung Cancer**

*Stephen Little, Ph.D., Chief Executive Officer, DxS Ltd.*

**Serum HER-2/neu as a Biomarker for HER-2 Positive Metastatic Breast Cancer (MBC)**

*Walter P. Carney, Ph.D., Head, Oncogene Science, Bayer HealthCare*

## IMPROVEMENTS IN OVARIAN CANCER SCREENING

**Translating Genomic Data into Multi-Analyte Serum Biomarkers for Early Detection of Ovarian Cancer**

*Garret M. Hampton, Ph.D., Senior Director, Biochemistry & Biomarker Development, Celgene*

**Proteomic Biomarkers for Ovarian Cancer: Discovery, Validation and Translation**

*Daniel W. Chan, Ph.D., DABCC, FACB, Professor of Pathology, Oncology, Radiology & Urology; Director of Clinical Chemistry Division, Department of Pathology; Director, Center for Biomarker Discovery, Johns Hopkins Medical Institutions*

**Serum Multimarker Assay for Early Detection of Ovarian Cancer**

*Anna Lokshin, Ph.D., Assistant Professor of Medicine, University of Pittsburgh*

**Gene Expression-Driven Cancer Diagnostics**

*Yixin Wang, Ph.D., Group Director, Discovery Research and Pharma Biomarker Support, Veridex, Johnson & Johnson*

## Panel Discussion

**Turning Discoveries into Clinical Products**

## Executive Strategy Panels

**Diagnostic Wish List**

*Moderator: Harry Glorikian, Managing Partner, Strategic Advisory, TSG Partners*

*Panelist: Ronald M. Krauss, M.D., Senior Scientist and Director, Atherosclerosis Research, Children's Hospital Oakland Research Institute; Guest Senior Scientist, Department of Genome Sciences, Lawrence Berkeley National Laboratory; and Adjunct Professor, Department of Nutritional Sciences, University of California, Berkeley*

**Personalized Medicine Coalition's Landscape Analysis**

*Edward Abrahams, Ph.D., Executive Director, Personalized Medicine Coalition*

**Commerical Opportunities in Molecular Diagnostics**

*Moderator: Keith F. Batchelder, M.D., Chief Executive Officer and Founder, Genomic Healthcare Strategies*

*Panelists: Carol Reed, M.D., Senior Vice President and Chief Medical Officer, Clinical Data, Inc. (tentative)*

*Stéphane Bancel, Executive Vice President, bioMérieux sa*

*Jean-Luc Vanderheyden, Ph.D., Molecular Imaging Leader, GE Healthcare (invited)*

## UNDERSTANDING EPIGENETICS AND METHYLATION PATTERNS OF DISEASE

**Epigenetics of Cancer Etiology**

*Andrew P. Feinberg, M.D., M.P.H., Professor, Molecular Medicine, Department of Medicine, Department of Oncology, Department of Molecular Biology & Genetics, Johns Hopkins University*

**QM-MSP-based Detection of Methylated Genes for Early Detection of Breast Cancer**

*Sara Sukumar, Ph.D., Professor of Oncology and Pathology, Johns Hopkins University*

**Biomarker Discovery: Mining the Cancer Epigenome**

*Jared Ordway, Ph.D., Senior Scientist and Program Leader, Discovery, Orion Genomics LLC*

## Panel Discussion

**Steps Needed to Translate DNA Methylation Biomarkers to Clinical Chemistry**

## CANCER MOLECULAR MARKERS

*(Shared session with Pathway Analysis)*

**Developing Pharmacodiagnostics for Cancer**

*Jan Trost Jorgensen, M.S. Pharm, Ph.D., Principal Scientist, Clinical Research, Dako*

**Biomarkers and Development of Targeted Therapies**

*Mikael von Euler, M.D., Ph.D., Vice President, Oncology Clinical Development, GlaxoSmithKline*

**Regulatory Aspects of Cancer Biomarkers - an EMEA Perspective**

*Michel E. Marty, Head, Centre for Therapeutic Innovations in Oncology and Haematology, Saint Louis University Hospital, and EMEA Advisor*

**Driving Down Development Costs by Using Biomarkers**

*Karol Sikora, M.A., MBBCh, Ph.D., FRCR, FRCP, FFPM, Professor of Cancer Medicine, Medical Solutions PLC*

**Detection of Cancer through Circulating DNA**

*Devin Dressman, Ph.D., Ludwig Center for Cancer Genetics & Therapeutics, The Johns Hopkins Kimmel Cancer Center (invited)*

TRACK : 6

*Second Annual*

# COMMERCIAL IMPLICATIONS OF STEM CELL RESEARCH

**February 28-March 2, 2007**

## BRIDGING Biology and Business to SUPPORT the Science

Supporting the science can only be achieved once scientists have the power to manipulate cells by a thorough understanding of how to "reprogram" stem cell behavior. However, the vision to launch a medical revolution takes commitment and cash. Cambridge Healthtech Institute's Second Annual Commercial Implications of Stem Cell Research continues the advancement of stem cell research by addressing the current reality and currency required to fulfill their power, potential, promise, and profitability.

### Scientific Advisory Committee

*Joe Bielitzki, DVM, University of Central Florida*
*Lee Buckler, LLB, Progenitor Cell Therapy*
*Robert Deans, Athersys, Inc.*
*Robert Harman, DVM, Vet-Stem, Inc.*
*Rosemarie Hunziker, Ph.D., NIH NIDCR*
*Mark Levenstein, Ph.D., WiCell Research Institute*
*Deepak Srivastava, M.D., University of California-San Francisco*
*Evan Snyder, M.D., Ph.D., The Burnham Institute*

### PLENARY KEYNOTES

**Clinical Qualification and Acceptance of Biomarkers and Surrogate Endpoints**

*Steven A. Williams, M.D., Ph.D., Executive Director & Worldwide Head, Clinical Technology & R&D, Pfizer Inc.*



**Partnering and Alliance Trends**

*Iain Dukes, M.A., Dphil., Vice President, Scientific & Technology Licensing, World Wide Business Development, GlaxoSmithKline*

### KICK-OFF KEYNOTE

**Selling the Stem Cell Dream**

*Irving Weissman, M.D., Ph.D., Director, Institute of Stem Cell Biology and Regenerative Medicine and Professor of Pathology and Developmental Biology, Stanford University (invited)*

### INTERACTIVE PANEL DISCUSSIONS

**Topics to be discussed:**

- Basic Biology
- Scale-up
- Regulation
- Funding
- Patient Advocacy Groups
- Public Perception
- Legal Issues

### BRIDGING BIOLOGY AND BUSINESS

**Human Embryonic Stem Cells – Promise and Progress**

*Thomas B. Okarma, M.D., Ph.D., President and CEO, Geron Corporation*

**The Paths around Stem Cell Intellectual Property**

*Kenneth Taymor, A.B, Attorney, MBV Law LLP; Lecturer, Stanford Law School (tentative)*

**Stem Cells: The Facts Not the Debate**

*Arnold Kriegstein, M.D., Ph.D., Director, Developmental and Stem Cell Biology and Professor, Neurology, University of California, San Francisco (invited)*

### STEM CELLS AND REGENERATIVE HEALING

**Enhancing Stem Cell Functionality in Aged Tissues**

*Thomas A. Rando, M.D., Ph.D., Associate Professor, Department of Neurology and Neurological, Sciences, Stanford University School of Medicine*

**Potential of Stem-Cell-Based Therapies for Heart Disease**

*Deepak Srivastava, M.D., Professor and Director Gladstone Institute of Cardiovascular Disease, Wilma and Adeline Pirag Distinguished Chair, Department of Pediatrics, University of California San Francisco*

**Molecular Imaging of Stem Cell Therapy**

*Joseph C. Wu, M.D., Ph.D., Instructor, Cardiovascular Medicine, Stanford University School of Medicine*

*"The continuity of discussion from process to product was both eye opening and exciting. It gives the CHI conference a distinct signature that highlights it as a premier conference for basic and applied scientists alike."*

*Mark L., Research Scientist, WiCell Research (2006 Alumnus)*

## Save the Date!

Save the Date!

Thursday, March 1, 5:30 pm - 7:00 pm

### "Wines of California & Dinner Reception"

Join us for a wine tasting dinner reception hosted by CHI. We will offer you the opportunity to network while experiencing California food and wine. The visiting wine makers will be pouring featured wines paired at tasting stations. Learn and discern with experts on hand.

Renaissance Parc 55 Hotel located in Union Square, a few blocks from the Moscone.
All are invited to enjoy the reception after Thursday's sessions.

## CHI's Intro-Net: Networking at Its Best! Maximize Your Experience Onsite at the Molecular Medicine Tri-Conference!

Cambridge Healthtech Institute's INTRO-NET

The Intro-Net offers you the opportunity to set up meetings with selected attendees before, during and after this conference, allowing you to connect to the key people that you want to meet. This online system was designed with your privacy in mind and is only available to registered session attendees of this event.

For more information, visit: www.Tri-Conference.com/intronet.asp

*"The Intro-Net was an excellent networking tool for me, and I made several direct meeting connections that have turned into real potential strategic relationships."*
*Eric B. D., Chairman/CEO, Genetic Assays, Inc.*

**TRACK : 7**

*Inaugural*

# CLINICAL TRIALS IN INDIA & ASIA

**February 28-March 2, 2007**

NEW!

**REDUCE costs, GAIN access to large patient populations and a GROWING consumer market**

Globalization of clinical trials is a growing trend driven by the need to reduce costs, gain access to large patient populations, and a growing consumer market. Making clinical trials more efficient is going to be key for success, and the leaders in this area need to be aware of how this rapidly changing environment can affect their business. This conference will explore strategies for implementing parallel trial design for US and overseas, that involves integrating data from disparate sites. The barriers to managing clinical trial sites overseas for this highly regulated and controlled area will be carefully weighed.

**SESSIONS INCLUDE:**

- Patient Registration and Recruitment
- Regulatory Concerns
- IP Protection
- Protecting Patient Safety
- Ensuring Ethical Compliance
- Managing Global Sites
- Access to Trained Foreign Clinical Investigators
- Approved Facilities, Monitoring Practices
- Handling Data from Disparate Sources
- Drug Registration

**TRACK : 8**

*Third Annual*

# TRENDS IN DRUG SAFETY

**February 28-March 2, 2007**

**FIRST! IMPROVING drug efficacy to OVERCOME safety issues**

**STRATEGIES FOR IMPROVING DRUG SAFETY**

- Manage risk proactively to lower candidate attrition
- Decrease failure with pharmacodynamic biomarkers
- Feed information from clinical trials into discovery phase
- Quantitate benefit-risk management
- Review case study in drug-redirecting
- Gain insights from imaging biomarkers
- Select compounds in man
- Choose the right animal model
- Predict human sensitivity
- Develop biomarker assays

**SESSIONS INCLUDE:**

- Cancer Biomarker Development
- Selecting First Dose in Humans
- How Many New Biomarkers do we Need? A Cost-Benefit Analysis of New Biomarkers
- Correlating Imaging With Clinical Experience
- Exploratory IND's and Microdosing

*"Trends in drug safety is an excellent forum for scientists and clinicians from academia and industry to learn about the needs, advances and opportunities occurring on the other side of the fence."*

*Eric A., Molecular Imaging Scientist, GE Healthcare (2006 Alumnis)*

**TRACK : 9**

*Inaugural*

# CANCER MOLECULAR MARKERS

**February 28-March 2, 2007**

NEW!

**SESSIONS INCLUDE:**

- Cancer Biomarker Development
- Case Histories in Serum-Based Markers
- Understanding Epigenetics and Methylation Patterns of Disease
- Expanding World of microRNAs: New Avenues for Dianostics and Therapy
- Improvements in Ovarian Cancer Screening
- Cancer Molecular Markers

## Present a Poster and Save $50!

- Your poster will be available to over 2,300 delegates
- You'll automatically be entered into our Poster Competition, where two winners will receive $500
- Receive $50 off your registration fee
- Your poster abstract will be published on the event cd
- Your research will be seen by leaders from top pharmaceutical, biotech, academic and government institutes
- **Plus!!** All posters will be included in the Molecular Medicine Tri-Conference Poster Abstract Book

Your abstract must be submitted, accepted, and registration paid in full by January 23, 2007.

# EXHIBIT AND SPONSOR INFORMATION

Molecular Medicine Tri-Conference is the predominant pharmaceutical/biotechnology event on the West Coast delivering an International audience of 2,300 decision-makers.

**60% of last year's delegates held Director level titles and higher!**

## Sponsorship Information

Sponsorship participation provides your company the opportunity to promote your company's solutions to this targeted and hard-to-reach market. Custom designed sponsorship programs enable you to competitively position your company as a leader in the biotech and pharma industries, and collect quality leads in formal and informal settings. CHI sales managers work with you to shape a sponsorship program that suits your companies sales objectives and budget.

## Sponsorship Opportunities:

- **Keynote Introductions & Chair Drops**
- **Podium Presentation Workshops**

Whether you are ready to present an exciting new technology, preparing for a new product launch or need feedback on a specific idea, this conference offers the perfect platform for you to present in front of your target audience. Workshops are embedded within the main conference program, allowing you to present for 30 minutes on a topic directed to your target audience.

- **Luncheon and Breakfast Workshops**

CHI will market your workshop and will continue to promote attendance on-site by providing a gift to be raffled. Business cards are also collected on your behalf for your post-workshop follow-up campaign.

- **Focus Group**

CHI will deliver 7-10 pre-qualified participants and provide the venue for your market research focus group.

- **Invitation-Only Hospitality Suite Reception or**
- **Invitation-Only Dinner**

Offers you the ability to hand-pick delegates to attend your function.

## "Vineyards of California" Dinner Reception

**A Premier Sponsorship!**

A wine tasting and dinner reception after Thursday's sessions at the Renaissance Parc 55 Hotel located in Union Square, a few blocks from the Moscone. An excellent opportunity to sponsor this very successful networking event! Last year over 400 delegates attended this fun and lively event.



## Exhibit Information

Exhibit Dates: February 28 – March 1, 2007

**Reserve space by October 30th to receive a discounted rate!**

Companies exhibiting will experience a highly qualified audience. Nearly 60% of attendees in 2006 held Director level titles and higher. 47% are from biotech companies, 26% from pharma! 77% of the audience represented the USA, 13% from Europe and 6% from Asia.

Please visit the web site for an updated floor plan and the current 2007 exhibitors and a full listing of exhibit benefits, or call David Karp at 781-972-5483, or Carol Dinerstein at 781-972-5471 for details.

### CHI Supports Your Participation!

### CHI's Cooperative Marketing Program

CHI is pleased to help market to your prospect list at a shared cost. We will offer your prospects a discounted rate to attend the conference on your behalf via mailing or email. CHI's Marketing Manager will customize a specific message to your target audience.

### For sponsorship and exhibit opportunities please contact:

**Carol Dinerstein**, 781-972-5471, dinerstein@healthtech.com

**David Karp**, 781-972-5483, dkarp@healthtech.com

## PRODUCT LAUNCH?

CHI will help market your product launch!

As an exhibitor announcing a new product, your launch news will be included in:

- One Joint ad in a key industry publication
- One Product Update email campaign to over 100,000 prospects and pre-registered delegates
- Product description in a press release announcing product launches at the event
- Corporate listing within an ad in the Program & Event Guide (distributed on-site)

## Exhibit Hours

**Wednesday, February 28:**
9:40am - 5:00pm

**Thursday, March 1:**
10:00am - 3:45pm

## 2007 Exhibitors & Sponsors

Analytical Biological Srvs.
AnalytiCon Discovery
Applied Biosystems
Biosearch Technologies
Biotage
Carna Biosciences
ChemBridge
ChemDiv
CHI Marketing Services
Dharmacon
DxS Ltd.
Exagen Diagnostics
FEI Company
GE Healthcare
GeneGo
Gentris Corporation
iAdvantage Software
Ingenuity Systems
INVITROGEN
Jubilant Biosys
Kalexsyn Inc.
Key Organics Ltd.
Kodak Molecular Imaging
Nanosyn Inc.
NuGEN Inc.
Oxonica Inc.
Pall Life Sciences
Peakdale Molecular
PharmaCore Inc.
PreClinoMics Inc.
Progenitor Cell Therapy
QIAGEN Inc.
Reaction Biology
Seradyn
SiDMAP
Siemens Medical Solutions
Source MDx
Zygogen

# Venue, Hotel and Travel Information

**Conference & Exhibit Venue:**

The Moscone North
Convention Center
747 Howard Street
San Francisco, CA 94103





**Headquarter Hotel:**

Renaissance Parc 55 Hotel
55 Cyril Magnin Street
San Francisco, CA 94102
Special Group Rate: $189
Reservation Cut Off Date:
February 6, 2007

## Travel Information



### "Only in San Francisco"

Take a family vacation to discover San Francisco. Enjoy all the "City by the Bay" has to offer. Take a cruise over to Alcatraz, walk along Fisherman's Wharf, have dim sum in Chinatown, stroll through historic North Beach. Find out more about these and everything else San Francisco has to offer at www.onlyinsanfrancisco.com

**Flight Discount:**

Discount fares are available on United, United Express, United code share flights (UA*) operated by US Airways, and US Airways Express.
You can receive up to a 15% discount off if you or your travel agent calls United's toll-free number 1-800-521-4041. Reference Meeting ID Number 579YS.

**Car Rental Discount:**

Special discount rentals have been established with AVIS for this conference.
You can reserve online at www.tri-conference.com/hotel.asp or call AVIS directly at 800-331-1600. You must reference your Avis Worldwide Discount (AWD) Number J868190.

**To make reservations online go to**
www.Tri-Conference.com/hotel.asp
or call
1-800-697-3103 or 415-392-8000 and
ask for the
**Molecular Medicine Tri-Conference**
group rate.

Reservations made after the cut-off date or after the group room block has been filled (whichever comes first) will be accepted on a space and-rate availability basis. Rooms are limited, so please book early.

A warmly appointed luxury hotel, situated in the heart of San Francisco, the hotel is 2 blocks from the renowned Union Square shopping area and theatre district; within walking distance of the San Francisco Museum of Modern Art and the Yerba Buena Gardens; near the Moscone Convention Center and financial district. You're just minutes from the East Bay, with convenient access to BART (Bay Area Rapid Transit), and the cable car is only a half-block away.

## Sponsoring Publications:

Asia Monitor
American Pharmaceutical Outsourcing
American Pharmaceutical Review
BioDrugs
Business Monitor international
Cancer Drug News
Chemical Biology & Drug Design
Drug Discovery & Development
Drug Development and Industrial Pharmacy
Drug Discovery News
Drug Safety
Emerging Europe Monitor
espicom Diagnostics Focus
European Biotechnology News
G&P
Journal of Business Strategy
the Journal of Molecular Diagnostics
Inpharma
Molecular Diagnosis & Therapy
Lab Manager
NGP NextGen Pharmaceutical
Pharma Company Insight
SYNTHESIS
SYNLETT
SYNFACTS
THOMSON CENTERWATCH
wpm World Pharmaceutical Markets

## Web Partners:

bio.com Life on the Net
biolexis for a better deal http://www.biolexis.com
BIOSCREENING.COM DRUG DISCOVERY PORTAL
BioSpace
Cell Therapy NEWS
CanBiotech Biotechnology Portal & B2B Marketplace
selectscience.net The Scientists' Choice
hum-molgen.org central gateway to HUMan MOLecular GENetics
www.PharmCast.com Pharmaceutical Internet

## Supporting Organizations:

BAYBIO
SAN JOSE bio center

## ALUMNI DISCOUNT

**Receive 25% Off Your Registration!**

Cambridge Healthtech Institute (CHI) appreciates your past participation at the Molecular Medicine Tri-Conference. Through loyalty like yours, CHI has been able to build this event into a must attend for senior level decision-makers. As a result of the great loyalty you have shown us, we are pleased to extend to you the exclusive opportunity to save an additional 25% off the registration rate. Just check off the box marked Alumni Discount on the registration form to receive the discount!

*Please note: Our records must indicate you were an attendee of the Tri-Conference event in the past in order to qualify.*

# YES! Register me for CHI's Molecular Medicine Tri-Conference

MMTC P

**Conference: February 27-March 2, 2007 • Exhibits: February 28-March 1, 2007**
**Moscone North Convention Center • San Francisco, CA**

**To Register** **Web:** www.Tri-Conference.com • **Phone:** 781-972-5400 toll-free in the U.S.:888-999-6288
**Fax:** 781-972-5425 • **Mail:** 250 First Avenue, Suite 300 Needham, MA 02494 USA

**REGISTER 3 — 4TH IS FREE**

Individuals must register and submit completed registration forms together for discount to apply. Please reproduce this registration form as needed.

❒ Yes! I would like a free subscription to: PharmaDD

## 1. REGISTRATION INFORMATION

❒ Mr. ❒ Ms. ❒ Mrs. ❒ Dr. ❒ Prof.

Name Job Title

Div./Dept. Company

Address

City/State/Postal Code Country

Telephone

Would you like to receive CHI event updates via fax? ❒ Yes ❒ No Fax

Email*

**Email is not a mandatory field. However, by not supplying your email you will not receive pre-conference access to presenter materials, conference updates and networking opportunities.*

## 2. PRICING INFORMATION

| | Commercial | Academic, Government, Hospital-Affiliated |
|---|---|---|
| **Track Pricing (February 28 - March 2)** | | |
| **Access to 200+ Presentations Covering 9 Tracks, CHI's Intro-Net, Scientific Posters and More!** | | |
| Early Registration until October 27, 2006 | ❒$1495 | ❒ $845 |
| Advance Registration until January 26, 2007 | ❒$1645 | ❒ $995 |
| Registrations after January 26, 2007 and onsite | ❒$1845 | ❒$1045 |

### Track Selection: (REQUIRED)

**CHOOSE ONE: Please indicate the one track you are most likely to attend.**

❒ Track 1: Pathway Analysis
❒ Track 2: R & D Strategies
❒ Track 3: Mastering Medicinal Chemistry
❒ Track 4: Preclinical Development
❒ Track 5: Molecular Diagnostics
❒ Track 6: Stem Cell Research
❒ Track 7: Clinical Trials in India & Asia
❒ Track 8: Trends in Drug Safety
❒ Track 9: Cancer Molecular Markers

### Pre-Conference Events (February 27)

**Choose 1 Short Course**
❒$695 • Commercial
❒$345 • Academic, Government, Hospital-Affiliated

**Choose 2 Short Courses (BEST VALUE!)**
❒$995 • Commercial
❒$595 • Academic, Government, Hospital-Affiliated

**Dinner**
❒ $495

**Morning** *(check one box only)*
❒ (SC1) Biotech Pharma Partnership - Part I
❒ (SC2) Global Strategies Morning Course
❒ (SC3) Novel Therapies for CNS Disorders
❒ (SC4) Microreactors
❒ (SC5) Circulating Tumor Cells
❒ (SC6) Preclinical Morning Course

**Afternoon** *(check one box only)*
Biotech Pharma Partnership - Part II
❒ (SC7) Diagnostics
❒ (SC8) Biomarkers
❒ (SC9) Cancer Therapeutics
❒ (SC10) Business War Game
❒ (SC11) ADMET Case Studies
❒ (SC12) Late-PCR
❒ (SC13) Microdosing
❒ (SC14) Stem Cell Course

**Evening** *(check one box only)*
❒ (DC15) New Ways to Partner

### Discounts*

❒ Poster ($50 off) ❒ Alumni (25% off ) ❒ BayBio Member (20% off)

** (See pg 11 for Alumni details • Alumni and Bay Bio Discount cannot be combined • Discounts not applicable on Pre-Conference Events only registrations)*

❒ Yes, I want to receive the Annual Biotech 2006 - Life Sciences: A Changing Prescription book by G. Steven Burrill (a $295 value)
*(To qualify you must be one of the first 50 people to register for 1 Track plus, at least 1 Short Course)*

**Multi-pack Discount: Purchase presentation materials for the entire event for only $750.**
CD Includes presentation material from all nine tracks, poster abstracts and more.
❒ I cannot attend but would like to purchase the event CD for $750 (plus shipping) (Massachusetts delivery will include 5% sales tax).

## 3. PAYMENT INFORMATION

❒ Enclosed is a check or money order payable to Cambridge Healthtech Institute, drawn on a U.S. bank, in U.S. currency.

❒ Invoice me, but reserve my space with credit card information listed below. **Invoices unpaid two weeks prior to conference will be billed to credit card at full registration rate. Invoices must be paid in full and checks received by the deadline date to retain registration discount.** If you plan to register on site, please check with CHI beforehand for space availability.

❒ Please charge: ❒ AMEX (15 digits) ❒ Visa (13-16 digits) ❒ MasterCard (16 digits) ❒ Diners Club (14 digits)

Card # Exp.Date

Cardholder Signature

Cardholder's Address (if different from above)

City/State/Postal Code Country

## 4. FAX OR MAIL YOUR REGISTRATION TO:

Cambridge Healthtech Institute, 250 First Avenue, Suite 300, Needham, MA 02494
Phone: 781-972-5400 or toll-free in the U.S. 888-999-6288 • Fax: 781-972-5425 • www.Tri-Conference.com

**Cambridge Healthtech Institute**
250 First Avenue, Suite 300
Needham, MA 02494

Please refer to the Registration Code below:
Keycode:

****PRESENT A POSTER AND SAVE $50:** Cambridge Healthtech Institute encourages attendees to gain further exposure by presenting their work in the poster sessions. To secure a poster board and inclusion in the conference CD, your abstract must be submitted, accepted and registration paid in full by January 23, 2007. Register online to use the Poster Abstract Submission form or, if you register by phone, fax, or mail, you will receive Poster Abstract Submission guidelines via email.

❒ I am interested in presenting a poster at Molecular Medicine Tri-Conference, and will submit a completed one-page abstract by January 23, 2007. (Please Note: Registration must be paid in full to present poster.)
Title

### ADDITIONAL REGISTRATION DETAILS

Each registration includes all conference sessions, posters and exhibits, food functions, and a copy of the conference CD.

### GROUP DISCOUNTS

Special rates are available for multiple attendees from the same organization. Contact David Cunningham at 781-972-5472 to discuss your options and take advantage of the savings.

### HANDICAPPED EQUAL ACCESS

In accordance with the ADA, Cambridge Healthtech Institute is pleased to arrange special accommodations for attendees with special needs. All requests for such assistance must be submitted in writing to CHI at least 30 days prior to the start of the meeting.

### SUBSTITUTION/CANCELLATION POLICY

In the event that you need to cancel a registration, you may:

- Transfer your registration to a colleague within your organization
- Credit your registration to another Cambridge Healthtech Institute program
- Request a refund minus a $100 processing fee per conference
- Request a refund minus the cost ($750) of ordering a copy of the CD

NOTE: Cancellations will only be accepted up to two weeks prior to the conference.

**Program and speakers are subject to change.**

Video and/or audio recording of any kind is prohibited onsite at all CHI events.